MolMed S.p.A. | Ownership
Companies that own MolMed S.p.A.
Airain Ltd.
24,037,678
5.19%
0
100%
06/05/2018
Banca Ifigest SpA (Investment Management)
3,179,879
0.69%
1,856,729
1.88%
03/29/2018
Allianz Global Investors GmbH (France)
2,242,594
0.48%
-6,766
0%
05/31/2018
ZENIT SGR SpA
1,656,926
0.36%
0
0.7%
07/31/2018
AXA Investment Managers (Paris) SA
1,600,000
0.35%
-400,000
0.01%
12/31/2017
Azimut Capital Management SGR SpA
1,450,000
0.31%
0
0.01%
06/30/2017
Invesco Asset Management Ltd.
1,205,648
0.26%
1,205,648
0%
03/29/2018
Mediolanum Gestione Fondi SGRpA
799,035
0.17%
0
0.03%
08/31/2018
Medical Strategy GmbH
710,500
0.15%
-36,000
0.18%
11/30/2017
Investitori SGR SpA
700,000
0.15%
700,000
0.07%
03/29/2018
| Address |
Via Olgettina, 58
Milan Milan 20132
Italy
|
|
Employees
|
- |
| Website |
http://www.molmed.it |
| Updated |
09/14/2018 |
| Molecular Medicine SpA is a medical biotechnology company which focuses on the research, development and clinical validation of therapies to treat cancer. The company's approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. Its pipeline includes antitumor therapeutics in clinical and preclinical development: Zalmoxis (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression. |
